The global genetic engineering drug market is expected to grow at a CAGR of 7.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of chronic diseases and rising demand for personalized medicine. The North American region is expected to dominate the global genetic engineering drug market in terms of revenue, followed by Europe and Asia Pacific.
The global genetic engineering drug market has been segmented on the basis of type, application, and region. On the basis of type, it has been classified into monoclonal antibody (MAB), recombinant human erythropoietin (rHuEPO), recombinant human interferon (rHuIFN), recombinant human growth hormone (rHuGH) and recombinant human insulin (rHuIns). On the basis of application, it has been classified into <30 years old population group; 30-60 years old population group; >60 years old population group; and others. On the basis of region, it has been classified into North America; Latin America; Europe; Asia Pacific & Middle East & Africa regions.
- Increasing awareness about genetic engineering drugs among physicians and patients is also expected to fuel the growth of this market in the near future.
- Technological advancements in gene editing techniques are also expected to drive demand for these drugs in the coming years, as they offer more precise treatment options for patients with specific genetic mutations or conditions that cannot be treated with conventional therapies or surgery alone.
Industry Growth Insights published a new data on “Genetic Engineering Drug Market”. The research report is titled “Genetic Engineering Drug Market research by Types (Monoclonal Antibody, Recombinant Human Erythropoietin, Recombinant Human Interferon, Recombinant Human Growth Hormone, Recombinant Human Insulin), By Applications (<30 Years Old, 30 Years Old-60 Years Old, >60 Years Old), By Players/Companies Shanghai Lansheng Guojian Pharmaceutical, Biotech Pharmaceutical, Anhui Anke Biotechnology, GeneScience Pharmaceuticals, Beijing SL Pharmaceutical, Jiangsu Sihuan Bioengineering, Shenzhen Neptunus Interlong Bio-Technique, 3SBio, Tonghua Dongbao Pharmaceutical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Genetic Engineering Drug Market Research Report
By Type
Monoclonal Antibody, Recombinant Human Erythropoietin, Recombinant Human Interferon, Recombinant Human Growth Hormone, Recombinant Human Insulin
By Application
<30 Years Old, 30 Years Old-60 Years Old, >60 Years Old
By Companies
Shanghai Lansheng Guojian Pharmaceutical, Biotech Pharmaceutical, Anhui Anke Biotechnology, GeneScience Pharmaceuticals, Beijing SL Pharmaceutical, Jiangsu Sihuan Bioengineering, Shenzhen Neptunus Interlong Bio-Technique, 3SBio, Tonghua Dongbao Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Genetic Engineering Drug Market Report Segments:
The global Genetic Engineering Drug market is segmented on the basis of:
Types
Monoclonal Antibody, Recombinant Human Erythropoietin, Recombinant Human Interferon, Recombinant Human Growth Hormone, Recombinant Human Insulin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
<30 Years Old, 30 Years Old-60 Years Old, >60 Years Old
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Shanghai Lansheng Guojian Pharmaceutical
- Biotech Pharmaceutical
- Anhui Anke Biotechnology
- GeneScience Pharmaceuticals
- Beijing SL Pharmaceutical
- Jiangsu Sihuan Bioengineering
- Shenzhen Neptunus Interlong Bio-Technique
- 3SBio
- Tonghua Dongbao Pharmaceutical
Highlights of The Genetic Engineering Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibody
- Recombinant Human Erythropoietin
- Recombinant Human Interferon
- Recombinant Human Growth Hormone
- Recombinant Human Insulin
- By Application:
- <30 Years Old
- 30 Years Old-60 Years Old
- >60 Years Old
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genetic Engineering Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Genetic engineering is the process of manipulating genes to change their function. This can be done by inserting new genes into a plant or animal, or by altering the function of existing genes. Drugs that are produced through genetic engineering are typically designed to treat specific diseases or conditions.
Some of the major companies in the genetic engineering drug market are Shanghai Lansheng Guojian Pharmaceutical, Biotech Pharmaceutical, Anhui Anke Biotechnology, GeneScience Pharmaceuticals, Beijing SL Pharmaceutical, Jiangsu Sihuan Bioengineering, Shenzhen Neptunus Interlong Bio-Technique, 3SBio, Tonghua Dongbao Pharmaceutical.
The genetic engineering drug market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Genetic Engineering Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Genetic Engineering Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Genetic Engineering Drug Market - Supply Chain
4.5. Global Genetic Engineering Drug Market Forecast
4.5.1. Genetic Engineering Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Genetic Engineering Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Genetic Engineering Drug Market Absolute $ Opportunity
5. Global Genetic Engineering Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Genetic Engineering Drug Market Size and Volume Forecast by Type
5.3.1. Monoclonal Antibody
5.3.2. Recombinant Human Erythropoietin
5.3.3. Recombinant Human Interferon
5.3.4. Recombinant Human Growth Hormone
5.3.5. Recombinant Human Insulin
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Genetic Engineering Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Genetic Engineering Drug Market Size and Volume Forecast by Application
6.3.1. <30 Years Old
6.3.2. 30 Years Old-60 Years Old
6.3.3. >60 Years Old
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Genetic Engineering Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Genetic Engineering Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Genetic Engineering Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Genetic Engineering Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Genetic Engineering Drug Demand Share Forecast, 2019-2029
9. North America Genetic Engineering Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Genetic Engineering Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Genetic Engineering Drug Market Size and Volume Forecast by Application
9.4.1. <30 Years Old
9.4.2. 30 Years Old-60 Years Old
9.4.3. >60 Years Old
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Genetic Engineering Drug Market Size and Volume Forecast by Type
9.7.1. Monoclonal Antibody
9.7.2. Recombinant Human Erythropoietin
9.7.3. Recombinant Human Interferon
9.7.4. Recombinant Human Growth Hormone
9.7.5. Recombinant Human Insulin
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Genetic Engineering Drug Demand Share Forecast, 2019-2029
10. Latin America Genetic Engineering Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Genetic Engineering Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Genetic Engineering Drug Market Size and Volume Forecast by Application
10.4.1. <30 Years Old
10.4.2. 30 Years Old-60 Years Old
10.4.3. >60 Years Old
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Genetic Engineering Drug Market Size and Volume Forecast by Type
10.7.1. Monoclonal Antibody
10.7.2. Recombinant Human Erythropoietin
10.7.3. Recombinant Human Interferon
10.7.4. Recombinant Human Growth Hormone
10.7.5. Recombinant Human Insulin
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Genetic Engineering Drug Demand Share Forecast, 2019-2029
11. Europe Genetic Engineering Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Genetic Engineering Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Genetic Engineering Drug Market Size and Volume Forecast by Application
11.4.1. <30 Years Old
11.4.2. 30 Years Old-60 Years Old
11.4.3. >60 Years Old
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Genetic Engineering Drug Market Size and Volume Forecast by Type
11.7.1. Monoclonal Antibody
11.7.2. Recombinant Human Erythropoietin
11.7.3. Recombinant Human Interferon
11.7.4. Recombinant Human Growth Hormone
11.7.. Recombinant Human Insulin
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Genetic Engineering Drug Demand Share, 2019-2029
12. Asia Pacific Genetic Engineering Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Genetic Engineering Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Genetic Engineering Drug Market Size and Volume Forecast by Application
12.4.1. <30 Years Old
12.4.2. 30 Years Old-60 Years Old
12.4.3. >60 Years Old
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Genetic Engineering Drug Market Size and Volume Forecast by Type
12.7.1. Monoclonal Antibody
12.7.2. Recombinant Human Erythropoietin
12.7.3. Recombinant Human Interferon
12.7.4. Recombinant Human Growth Hormone
12.7.5. Recombinant Human Insulin
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Genetic Engineering Drug Demand Share, 2019-2029
13. Middle East & Africa Genetic Engineering Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Genetic Engineering Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Genetic Engineering Drug Market Size and Volume Forecast by Application
13.4.1. <30 Years Old
13.4.2. 30 Years Old-60 Years Old
13.4.3. >60 Years Old
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Genetic Engineering Drug Market Size and Volume Forecast by Type
13.7.1. Monoclonal Antibody
13.7.2. Recombinant Human Erythropoietin
13.7.3. Recombinant Human Interferon
13.7.4. Recombinant Human Growth Hormone
13.7.5. Recombinant Human Insulin
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Genetic Engineering Drug Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Genetic Engineering Drug Market: Market Share Analysis
14.2. Genetic Engineering Drug Distributors and Customers
14.3. Genetic Engineering Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Shanghai Lansheng Guojian Pharmaceutical
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Biotech Pharmaceutical
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Anhui Anke Biotechnology
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GeneScience Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Beijing SL Pharmaceutical
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Jiangsu Sihuan Bioengineering
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Shenzhen Neptunus Interlong Bio-Technique
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. 3SBio
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Tonghua Dongbao Pharmaceutical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
